For Your Information
FTC Approves Final Order Settling Charges that LabCorp's Proposed Acquisition of Orchid Cellmark Inc. was Anticompetitive in Market for Paternity Testing Services
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Laboratory Corporation of America Holdings' (LabCorp) proposed acquisition of rival firm Orchid Cellmark Inc. (Orchid) would have illegally reduced competition in the U.S. market for paternity testing services provided to government agencies. The final order settling the FTC's charges requires LabCorp to sell the portion of Orchid's U.S. paternity testing business that is focused on sales to government agencies to another testing company, DNA Diagnostics Center.
The Commission vote approving the final order was 4-0. (FTC File No. 111-0155, Docket No. C-4341; the staff contact is Michael Barnett, Bureau of Competition, 202-326-2362; see press release dated December 8, 2011.)
The Federal Trade Commission works to promote competition, and to protect and educate consumers. The FTC will never demand money, make threats, tell you to transfer money, or promise you a prize. You can learn more about how competition benefits consumers, file an antitrust complaint, or comment on a proposed merger. For the latest news and resources, follow the FTC on social media, subscribe to press releases, and read our blog.
Contact Information
202-326-2180